Cargando…

Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection

BACKGROUND: The JAK2 V617F mutation is the most frequent somatic change in myeloproliferative neoplasms, making it an important tumour-specific marker for diagnostic purposes and for the detection of minimal residual disease. Sensitive quantitative assays are required for both applications, particul...

Descripción completa

Detalles Bibliográficos
Autores principales: Zapparoli, Giada V, Jorissen, Robert N, Hewitt, Chelsee A, McBean, Michelle, Westerman, David A, Dobrovic, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658971/
https://www.ncbi.nlm.nih.gov/pubmed/23617802
http://dx.doi.org/10.1186/1471-2407-13-206
_version_ 1782270373895602176
author Zapparoli, Giada V
Jorissen, Robert N
Hewitt, Chelsee A
McBean, Michelle
Westerman, David A
Dobrovic, Alexander
author_facet Zapparoli, Giada V
Jorissen, Robert N
Hewitt, Chelsee A
McBean, Michelle
Westerman, David A
Dobrovic, Alexander
author_sort Zapparoli, Giada V
collection PubMed
description BACKGROUND: The JAK2 V617F mutation is the most frequent somatic change in myeloproliferative neoplasms, making it an important tumour-specific marker for diagnostic purposes and for the detection of minimal residual disease. Sensitive quantitative assays are required for both applications, particularly for the monitoring of minimal residual disease, which requires not only high sensitivity but also very high specificity. METHODS: We developed a highly sensitive probe-free quantitative mutant-allele detection method, Quantitative Threefold Allele-Specific PCR (QuanTAS-PCR), that is performed in a closed-tube system, thus eliminating the manipulation of PCR products. QuantTAS-PCR uses a threefold approach to ensure allele-specific amplification of the mutant sequence: (i) a mutant allele-specific primer, (ii) a 3′dideoxy blocker to suppress false-positive amplification from the wild-type template and (iii) a PCR specificity enhancer, also to suppress false-positive amplification from the wild-type template. Mutant alleles were quantified relative to exon 9 of JAK2. RESULTS: We showed that the addition of the 3′dideoxy blocker suppressed but did not eliminate false-positive amplification from the wild-type template. However, the addition of the PCR specificity enhancer near eliminated false-positive amplification from the wild-type allele. Further discrimination between true and false positives was enabled by using the quantification cycle (Cq) value of a single mutant template as a cut-off point, thus enabling robust distinction between true and false positives. As 10,000 JAK2 templates were used per replicate, the assay had a sensitivity of 1/10(-4) per replicate. Greater sensitivity could be reached by increasing the number of replicates analysed. Variation in replicates when low mutant-allele templates were present necessitated the use of a statistics-based approach to estimate the load of mutant JAK2 copies. QuanTAS-PCR showed comparable quantitative results when validated against a commercial assay. CONCLUSIONS: QuanTAS-PCR is a simple, cost-efficient, closed-tube method for JAK2 V617F mutation quantification that can detect very low levels of the mutant allele, thus enabling analysis of minimal residual disease. The approach can be extended to the detection of other recurrent single nucleotide somatic changes in cancer.
format Online
Article
Text
id pubmed-3658971
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36589712013-05-23 Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection Zapparoli, Giada V Jorissen, Robert N Hewitt, Chelsee A McBean, Michelle Westerman, David A Dobrovic, Alexander BMC Cancer Technical Advance BACKGROUND: The JAK2 V617F mutation is the most frequent somatic change in myeloproliferative neoplasms, making it an important tumour-specific marker for diagnostic purposes and for the detection of minimal residual disease. Sensitive quantitative assays are required for both applications, particularly for the monitoring of minimal residual disease, which requires not only high sensitivity but also very high specificity. METHODS: We developed a highly sensitive probe-free quantitative mutant-allele detection method, Quantitative Threefold Allele-Specific PCR (QuanTAS-PCR), that is performed in a closed-tube system, thus eliminating the manipulation of PCR products. QuantTAS-PCR uses a threefold approach to ensure allele-specific amplification of the mutant sequence: (i) a mutant allele-specific primer, (ii) a 3′dideoxy blocker to suppress false-positive amplification from the wild-type template and (iii) a PCR specificity enhancer, also to suppress false-positive amplification from the wild-type template. Mutant alleles were quantified relative to exon 9 of JAK2. RESULTS: We showed that the addition of the 3′dideoxy blocker suppressed but did not eliminate false-positive amplification from the wild-type template. However, the addition of the PCR specificity enhancer near eliminated false-positive amplification from the wild-type allele. Further discrimination between true and false positives was enabled by using the quantification cycle (Cq) value of a single mutant template as a cut-off point, thus enabling robust distinction between true and false positives. As 10,000 JAK2 templates were used per replicate, the assay had a sensitivity of 1/10(-4) per replicate. Greater sensitivity could be reached by increasing the number of replicates analysed. Variation in replicates when low mutant-allele templates were present necessitated the use of a statistics-based approach to estimate the load of mutant JAK2 copies. QuanTAS-PCR showed comparable quantitative results when validated against a commercial assay. CONCLUSIONS: QuanTAS-PCR is a simple, cost-efficient, closed-tube method for JAK2 V617F mutation quantification that can detect very low levels of the mutant allele, thus enabling analysis of minimal residual disease. The approach can be extended to the detection of other recurrent single nucleotide somatic changes in cancer. BioMed Central 2013-04-24 /pmc/articles/PMC3658971/ /pubmed/23617802 http://dx.doi.org/10.1186/1471-2407-13-206 Text en Copyright © 2013 Zapparoli et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Technical Advance
Zapparoli, Giada V
Jorissen, Robert N
Hewitt, Chelsee A
McBean, Michelle
Westerman, David A
Dobrovic, Alexander
Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection
title Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection
title_full Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection
title_fullStr Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection
title_full_unstemmed Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection
title_short Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection
title_sort quantitative threefold allele-specific pcr (quantas-pcr) for highly sensitive jak2 v617f mutant allele detection
topic Technical Advance
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658971/
https://www.ncbi.nlm.nih.gov/pubmed/23617802
http://dx.doi.org/10.1186/1471-2407-13-206
work_keys_str_mv AT zapparoligiadav quantitativethreefoldallelespecificpcrquantaspcrforhighlysensitivejak2v617fmutantalleledetection
AT jorissenrobertn quantitativethreefoldallelespecificpcrquantaspcrforhighlysensitivejak2v617fmutantalleledetection
AT hewittchelseea quantitativethreefoldallelespecificpcrquantaspcrforhighlysensitivejak2v617fmutantalleledetection
AT mcbeanmichelle quantitativethreefoldallelespecificpcrquantaspcrforhighlysensitivejak2v617fmutantalleledetection
AT westermandavida quantitativethreefoldallelespecificpcrquantaspcrforhighlysensitivejak2v617fmutantalleledetection
AT dobrovicalexander quantitativethreefoldallelespecificpcrquantaspcrforhighlysensitivejak2v617fmutantalleledetection